Leuthold Group LLC Purchases New Stake in United Therapeutics Corporation $UTHR

Leuthold Group LLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 3rd quarter, HoldingsChannel reports. The fund acquired 7,546 shares of the biotechnology company’s stock, valued at approximately $3,163,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of UTHR. CWM LLC grew its holdings in United Therapeutics by 204.3% during the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after purchasing an additional 3,487 shares in the last quarter. AXQ Capital LP lifted its holdings in United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after buying an additional 3,235 shares in the last quarter. AE Wealth Management LLC boosted its position in United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after buying an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC grew its stake in shares of United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after acquiring an additional 2,975 shares in the last quarter. Finally, Optimize Financial Inc purchased a new stake in shares of United Therapeutics during the third quarter worth about $444,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. UBS Group increased their price target on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $483.25, for a total transaction of $4,010,975.00. Following the sale, the executive vice president owned 36,781 shares in the company, valued at $17,774,418.25. This represents a 18.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 506,214 shares of company stock valued at $244,093,753 in the last quarter. Insiders own 10.30% of the company’s stock.

United Therapeutics Price Performance

United Therapeutics stock opened at $475.85 on Thursday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $519.99. The company has a fifty day moving average price of $486.49 and a two-hundred day moving average price of $431.01. The company has a market cap of $20.49 billion, a PE ratio of 18.03, a P/E/G ratio of 2.52 and a beta of 0.85.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.